{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:38:25Z","timestamp":1792852705822,"version":"4.5.0"},"reference-count":169,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["RG\/F\/23\/110112"],"award-info":[{"award-number":["RG\/F\/23\/110112"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["PG\/23\/11184"],"award-info":[{"award-number":["PG\/23\/11184"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018955","name":"Leeds Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jtha.2025.11.033","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T16:49:19Z","timestamp":1767372559000},"page":"1213-1229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Novel and experimental anticoagulant strategies beyond current direct oral anticoagulants"],"prefix":"10.1016","volume":"24","author":[{"given":"Holly C.","family":"Dobbing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6310-5745","authenticated-orcid":false,"given":"Robert A.S.","family":"Ari\u00ebns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.11.033_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.108173","article-title":"Real-world safety profile of direct oral anticoagulants (DOACs): Disproportionality analysis of major bleeding events","volume":"34","author":"di Biase","year":"2025","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jtha.2025.11.033_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1476-4431.2009.00389.x","article-title":"The cell-based model of coagulation","volume":"19","author":"Smith","year":"2009","journal-title":"J Vet Emerg Crit Care (San Antonio)"},{"key":"10.1016\/j.jtha.2025.11.033_bib3","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3109\/10409238.2015.1050550","article-title":"How it all starts: initiation of the clotting cascade","volume":"50","author":"Smith","year":"2015","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.1016\/j.jtha.2025.11.033_bib4","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1038\/s41467-021-25888-7","article-title":"Identification of the factor XII contact activation site enables sensitive coagulation diagnostics","volume":"12","author":"Heestermans","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtha.2025.11.033_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1084\/jem.20050664","article-title":"Defective thrombus formation in mice lacking coagulation factor XII","volume":"202","author":"Renn\u00e9","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1084\/jem.20052458","article-title":"Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis","volume":"203","author":"Kleinschnitz","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib7","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1182\/blood-2011-05-355248","article-title":"Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding","volume":"118","author":"Revenko","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1055\/s-0038-1642386","article-title":"The prevalence of moderate and severe FXII (Hageman factor) deficiency among the normal population: evaluation of the incidence of FXII deficiency among 300 healthy blood donors","volume":"71","author":"Halbmayer","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib9","first-page":"117","article-title":"Thromboembolism and bleeding tendency in congenital factor XII deficiency\u2014a study on 74 subjects from 14 Swiss families","volume":"65","author":"L\u00e4mmle","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-0038-1656366","article-title":"The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and\/or arterial thromboembolism","volume":"68","author":"Halbmayer","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib11","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2009-05-219915","article-title":"Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology","volume":"114","author":"Cushman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2141.1994.tb04937.x","article-title":"John Hageman\u2019s factor and deep-vein thrombosis: Leiden Thrombophilia Study","volume":"87","author":"Koster","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.11.033_bib13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fmed.2018.00066","article-title":"Cell receptor and cofactor interactions of the contact activation system and factor XI","volume":"5","author":"Pathak","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtha.2025.11.033_bib14","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/blood-2005-12-023697","article-title":"Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII","volume":"108","author":"Doggen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/jth.12531","article-title":"Antigen levels of coagulation factor XII, coagulation factor XI and prekallikrein, and the risk of myocardial infarction and ischemic stroke in young women","volume":"12","author":"Siegerink","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.5551\/jat.3673","article-title":"Coagulation factors II, V, IX, X, XI, and XII, plasminogen, and alpha-2 antiplasmin and risk of coronary heart disease","volume":"17","author":"Yamagishi","year":"2010","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jtha.2025.11.033_bib17","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000297966","article-title":"Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study","volume":"29","author":"Suri","year":"2010","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.jtha.2025.11.033_bib18","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1538-7836.2007.02530.x","article-title":"Evidence of a U-shaped association between factor XII activity and overall survival","volume":"5","author":"Endler","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/asheducation-2014.1.66","article-title":"Epidemiologic and clinical data linking factors XI and XII to thrombosis","volume":"2014","author":"Key","year":"2014","journal-title":"Hematology"},{"key":"10.1016\/j.jtha.2025.11.033_bib20","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.thromres.2015.06.028","article-title":"The role of activated coagulation factor XII in overall clot stability and fibrinolysis","volume":"136","author":"Konings","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.11.033_bib21","first-page":"247","article-title":"The factor XIIa blocking antibody 3F7: a safe anticoagulant with anti-inflammatory activities","volume":"3","author":"Worm","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib22","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1055\/s-0039-1692439","article-title":"The safety and efficacy of novel agents targeting factor XI and XII in early phase human trials","volume":"45","author":"DeLoughery","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib23","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","article-title":"Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Craig","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.11.033_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00408-023-00615-9","article-title":"Efficacy and safety of garadacimab in combination with standard of care treatment in patients with severe COVID-19","volume":"201","author":"Papi","year":"2023","journal-title":"Lung"},{"key":"10.1016\/j.jtha.2025.11.033_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006804","article-title":"A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk","volume":"6","author":"Larsson","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib26","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/bjh.13990","article-title":"FXIIa inhibitor rHA-Infestin-4: safe thromboprotection in experimental venous, arterial and foreign surface-induced thrombosis","volume":"173","author":"May","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.11.033_bib27","doi-asserted-by":"crossref","first-page":"7898","DOI":"10.1038\/s41467-024-51745-4","article-title":"A single-domain antibody targeting factor XII inhibits both thrombosis and inflammation","volume":"15","author":"Xu","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtha.2025.11.033_bib28","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2013-04-499111","article-title":"Factor XII inhibition reduces thrombus formation in a primate thrombosis model","volume":"123","author":"Matafonov","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib29","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","article-title":"Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits","volume":"123","author":"Yau","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib30","first-page":"19","article-title":"Factors XI and XII as targets for new anticoagulants","volume":"4","author":"Weitz","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtha.2025.11.033_bib31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib32","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1080\/10245332.2015.1112495","article-title":"Congenital factor XI and factor VII deficiencies assure an apparent opposite protection against arterial or venous thrombosis: an intriguing observation","volume":"21","author":"Girolami","year":"2016","journal-title":"Hematology"},{"key":"10.1016\/j.jtha.2025.11.033_bib33","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib34","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1538-7836.2012.04653.x","article-title":"Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: Results from the European Network of Rare Bleeding Disorders","volume":"10","author":"Peyvandi","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib35","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.3390\/jcm12154890","article-title":"Persistently high levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"12","author":"Spiezia","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-023-01905-5","article-title":"Elevated plasma factor XI predicts cardiovascular events in patients with type 2 diabetes: a long-term observational study","volume":"22","author":"Paszek","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jtha.2025.11.033_bib37","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib38","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.11.033_bib39","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib40","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib41","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/S0140-6736(25)02097-5","article-title":"Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials","volume":"406","author":"Weitz","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.11.033_bib43","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib44","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","article-title":"Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients with ESRD","volume":"7","author":"Walsh","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jtha.2025.11.033_bib45","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.kint.2024.02.024","article-title":"A phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis","volume":"106","author":"Winkelmayer","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.jtha.2025.11.033_bib46","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41591-023-02794-7","article-title":"Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial","volume":"30","author":"Weitz","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib47","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.11.033_bib48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib49","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.11.033_bib50","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtha.2025.11.033_bib51","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.11.033_bib42","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/hematolrep16010016","article-title":"Drug\u2013drug interactions of FXI inhibitors: clinical relevance","volume":"16","author":"Ferri","year":"2024","journal-title":"Hematol Rep"},{"key":"10.1016\/j.jtha.2025.11.033_bib53","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib54","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","article-title":"The contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial","volume":"39","author":"Lorentz","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2025.11.033_bib55","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J Mol Biol"},{"key":"10.1016\/j.jtha.2025.11.033_bib56","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/rth2.12186","article-title":"BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: first evaluation of safety, pharmacodynamics, and pharmacokinetics","volume":"3","author":"Thomas","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib57","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa","volume":"20","author":"Yi","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib58","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1161\/CIRCULATIONAHA.113.002033","article-title":"Evolution and emergence of therapeutic monoclonal antibodies","volume":"127","author":"Foltz","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.11.033_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.903029","article-title":"Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on current evidence","volume":"9","author":"Nopp","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib60","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/MAT.0000000000002048","article-title":"Factor XI inhibition with heparin reduces clot formation in simulated pediatric extracorporeal membrane oxygenation","volume":"69","author":"Meyer","year":"2023","journal-title":"ASAIO J"},{"key":"10.1016\/j.jtha.2025.11.033_bib61","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/bloodadvances.2022007586","article-title":"Targeting the contact system in a rabbit model of extracorporeal membrane oxygenation","volume":"7","author":"Tweddell","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.11.033_bib62","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2014810118","article-title":"Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of factor XI","volume":"118","author":"Kearney","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2025.11.033_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1517109","article-title":"The wonders of anticoagulation","volume":"11","author":"Ten Cate","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib64","unstructured":"Study details. NCT05757869. A study of milvexian versus apixaban in participants with atrial fibrillation. ClinicalTrials.gov."},{"key":"10.1016\/j.jtha.2025.11.033_bib65","doi-asserted-by":"crossref","DOI":"10.1182\/hem.V22.3.202537","article-title":"Can abelacimab attenuate the risk of bleeding in patients with atrial fibrillation?","volume":"22","author":"Scott","year":"2025","journal-title":"Hematologist"},{"key":"10.1016\/j.jtha.2025.11.033_bib66","unstructured":"Study details. NCT05686070. A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk transient ischemic attack, a so-called mini stroke. ClinicalTrials.gov."},{"key":"10.1016\/j.jtha.2025.11.033_bib67","unstructured":"Study details. NCT05702034. A study of milvexian in participants after an acute ischemic stroke or high-risk transient ischemic attack\u2014LIBREXIA-STROKE. ClinicalTrials.gov."},{"key":"10.1016\/j.jtha.2025.11.033_bib68","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ahj.2025.02.011","article-title":"Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS)","volume":"285","author":"Gibson","year":"2025","journal-title":"Am Heart J"},{"key":"10.1016\/j.jtha.2025.11.033_bib69","unstructured":"Study details. NCT05171049. A study comparing abelacimab to apixaban in the treatment of cancer-associated VTE. ClinicalTrials.gov."},{"key":"10.1016\/j.jtha.2025.11.033_bib70","unstructured":"Study details. NCT05171075. A study comparing abelacimab to dalteparin in the treatment of gastrointestinal\/genitourinary cancer and associated VTE. ClinicalTrials.gov."},{"key":"10.1016\/j.jtha.2025.11.033_bib71","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1084\/jem.20091007","article-title":"Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis","volume":"206","author":"Decrem","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib72","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2019.08.1028","article-title":"Anticoagulation with an inhibitor of factors XIa and XIIa during cardiopulmonary bypass","volume":"74","author":"Pireaux","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.11.033_bib73","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1182\/blood.2021010684","article-title":"Cryo-EM structures of human coagulation factors V and Va","volume":"137","author":"Ruben","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib74","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jtha.2023.01.033","article-title":"Natural anticoagulant discovery, the gift that keeps on giving: finding FV-Short","volume":"21","author":"Dahlb\u00e4ck","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib75","doi-asserted-by":"crossref","first-page":"31869","DOI":"10.1016\/S0021-9258(18)31776-9","article-title":"The mechanism of inactivation of human factor V and human factor Va by activated protein C","volume":"269","author":"Kalafatis","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2025.11.033_bib76","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1538-7836.2003.t01-1-00553.x","article-title":"Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias","volume":"2","author":"Acharya","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib77","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/rth2.12091","article-title":"Factor V levels and risk of venous thrombosis: the MEGA case-control study","volume":"2","author":"Rietveld","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102330","article-title":"Factor V variants in bleeding and thrombosis","volume":"8","author":"Mohapatra","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib79","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.chembiol.2022.01.009","article-title":"Generation of an anticoagulant aptamer that targets factor V\/Va and disrupts the FVa-membrane interaction in normal and COVID-19 patient samples","volume":"29","author":"Soule","year":"2022","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.jtha.2025.11.033_bib80","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/j.1538-7836.2006.01957.x","article-title":"Factor V C2 domain contains a major thrombin-binding site responsible for thrombin-catalyzed factor V activation","volume":"4","author":"Suzuki","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib81","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/jth.14594","article-title":"The roles of factor Va and protein S in formation of the activated protein C\/protein S\/factor Va inactivation complex","volume":"17","author":"Gierula","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.883986","article-title":"Current knowledge on factor V Leiden mutation as a risk factor for recurrent venous thromboembolism: a systematic review and meta-analysis","volume":"9","author":"Eppenberger","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib83","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0140-6736(94)92497-X","article-title":"Activated protein C resistance caused by Arg506Gln mutation in factor Va","volume":"343","author":"Greengard","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.11.033_bib84","doi-asserted-by":"crossref","first-page":"eadk5836","DOI":"10.1126\/sciadv.adk5836","article-title":"TFPI\u03b1 anticoagulant function is highly dependent on protein S in vivo","volume":"10","author":"Petri","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.jtha.2025.11.033_bib85","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/rth2.12057","article-title":"Factor V-short and protein S as synergistic tissue factor pathway inhibitor (TFPI\u03b1) cofactors","volume":"2","author":"Dahlb\u00e4ck","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib86","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1172\/JCI69091","article-title":"Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPI\u03b1","volume":"123","author":"Vincent","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtha.2025.11.033_bib87","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/jth.13559","article-title":"The C-terminus of tissue factor pathway inhibitor-\u03b1 inhibits factor V activation by protecting the Arg1545 cleavage site","volume":"15","author":"van Doorn","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib88","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1182\/blood-2014-08-592733","article-title":"A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function","volume":"125","author":"Cunha","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib89","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/jth.15314","article-title":"F5-Atlanta: a novel mutation in F5 associated with enhanced East Texas splicing and FV-short production","volume":"19","author":"Zimowski","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib169","doi-asserted-by":"crossref","first-page":"9621","DOI":"10.3390\/app11209621","article-title":"Antisense-mediated down-regulation of factor V-short splicing in a liver cell line model","volume":"11","author":"Todaro","year":"2021","journal-title":"Appl Sci"},{"key":"10.1016\/j.jtha.2025.11.033_bib90","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/bi00350a035","article-title":"Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity","volume":"25","author":"Eaton","year":"1986","journal-title":"Biochemistry"},{"key":"10.1016\/j.jtha.2025.11.033_bib91","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1182\/blood.V99.11.3993","article-title":"A novel mechanism of factor VIII protection by von Willebrand factor from activated protein C-catalyzed inactivation","volume":"99","author":"Nogami","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib92","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jth.14343","article-title":"High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor","volume":"17","author":"Rietveld","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib93","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/ehjcvp\/pvae076","article-title":"Role of PCSK9 inhibitors in venous thromboembolism: current evidence and unmet clinical needs","volume":"10","author":"Zuin","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jtha.2025.11.033_bib94","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/s-0038-1676863","article-title":"PCSK9 in haemostasis and thrombosis: possible pleiotropic effects of PCSK9 inhibitors in cardiovascular prevention","volume":"119","author":"Paciullo","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib95","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.V92.2.496","article-title":"Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor","volume":"92","author":"Jacquemin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib96","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.V95.1.156","article-title":"A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor","volume":"95","author":"Jacquemin","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib97","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1538-7836.2006.01900.x","article-title":"Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody","volume":"4","author":"Jacquemin","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib98","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1538-7836.2008.03271.x","article-title":"A human monoclonal antibody inhibiting partially factor VIII activity reduces thrombus growth in baboons","volume":"7","author":"Jacquemin","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib99","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.thromres.2011.06.027","article-title":"Partial versus complete factor VIII inhibition in a mouse model of venous thrombosis","volume":"129","author":"Emmerechts","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.11.033_bib100","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1160\/TH13-01-0066","article-title":"Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial","volume":"109","author":"Verhamme","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib101","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1021\/bi5011688","article-title":"Cluster III of low-density lipoprotein receptor-related protein 1 binds activated blood coagulation factor VIII","volume":"54","author":"Kurasawa","year":"2015","journal-title":"Biochemistry"},{"key":"10.1016\/j.jtha.2025.11.033_bib102","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1161\/CIRCULATIONAHA.120.046397","article-title":"The effect of PCSK9 (proprotein convertase subtilisin\/kexin type 9) inhibition on the risk of venous thromboembolism","volume":"141","author":"Marston","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.11.033_bib103","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1538-7836.2007.02572.x","article-title":"Clearance mechanisms of von Willebrand factor and factor VIII","volume":"5","author":"Lenting","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib104","doi-asserted-by":"crossref","first-page":"22875","DOI":"10.1074\/jbc.M400531200","article-title":"The significance of circulating factor IXa in blood","volume":"279","author":"Butenas","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2025.11.033_bib105","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1309\/AJCPAGOR4Q2IIKUG","article-title":"Elevated factor IX activity is associated with an increased odds ratio for both arterial and venous thrombotic events","volume":"140","author":"Heikal","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jtha.2025.11.033_bib106","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1055\/s-0037-1614852","article-title":"An inhibitory anti-factor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis","volume":"82","author":"Feuerstein","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib107","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0049-3848(00)00299-1","article-title":"Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosis","volume":"100","author":"Toomey","year":"2000","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.11.033_bib108","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0140-6736(15)00515-2","article-title":"Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial","volume":"387","author":"Lincoff","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.11.033_bib109","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1538-7836.2007.02872.x","article-title":"Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study","volume":"6","author":"Eriksson","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib110","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/MOH.0000000000000445","article-title":"Fibrinogen and factor XIII: newly-recognized roles in venous thrombosis formation and composition","volume":"25","author":"Wolberg","year":"2018","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jtha.2025.11.033_bib111","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/j.1538-7836.2005.01365.x","article-title":"Fibrinogen and fibrin structure and functions","volume":"3","author":"Mosesson","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib112","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ejvs.2017.12.002","article-title":"Mechanical and biochemical role of fibrin within a venous thrombus","volume":"55","author":"Chandrashekar","year":"2018","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jtha.2025.11.033_bib113","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0022-2836(90)90376-W","article-title":"Electron microscope investigation of the early stages of fibrin assembly. Twisted protofibrils and fibers","volume":"216","author":"Medved","year":"1990","journal-title":"J Mol Biol"},{"key":"10.1016\/j.jtha.2025.11.033_bib114","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/bloodadvances.2023012186","article-title":"Congenital fibrinogen disorders: a retrospective clinical and genetic analysis of the Prospective Rare Bleeding Disorders Database","volume":"8","author":"Mohsenian","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.11.033_bib115","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1182\/blood-2010-11-316885","article-title":"Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice","volume":"117","author":"Machlus","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib116","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.68761","article-title":"Fibrinogen \u03b1C-subregions critically contribute blood clot fibre growth, mechanical stability, and resistance to fibrinolysis","volume":"10","author":"McPherson","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.jtha.2025.11.033_bib117","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2014-06-582866","article-title":"Natural history of patients with congenital dysfibrinogenemia","volume":"125","author":"Casini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib118","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/jth.14412","article-title":"Factor XIII topology: organization of B subunits and changes with activation studied with single-molecule atomic force microscopy","volume":"17","author":"Protopopova","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib119","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1042\/bj1410683","article-title":"Calcium-induced dissociation of human plasma factor XIII and the appearance of catalytic activity","volume":"141","author":"Cooke","year":"1974","journal-title":"Biochem J"},{"key":"10.1016\/j.jtha.2025.11.033_bib120","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bpj.2011.11.4016","article-title":"\u03b1-\u03b1 Cross-links increase fibrin fiber elasticity and stiffness","volume":"102","author":"Helms","year":"2012","journal-title":"Biophys J"},{"key":"10.1016\/j.jtha.2025.11.033_bib121","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.1182\/blood-2011-02-333203","article-title":"The antifibrinolytic function of factor XIII is exclusively expressed through \u03b12-antiplasmin cross-linking","volume":"117","author":"Fraser","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib122","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/bloodadvances.2017011890","article-title":"Factor XIII in plasma, but not in platelets, mediates red blood cell retention in clots and venous thrombus size in mice","volume":"2","author":"Kattula","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.11.033_bib123","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75234-y","article-title":"Impaired contraction of blood clots precedes and predicts postoperative venous thromboembolism","volume":"10","author":"Evtugina","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtha.2025.11.033_bib124","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/ATVBAHA.116.308622","article-title":"Contraction of blood clots is impaired in acute ischemic stroke","volume":"37","author":"Tutwiler","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2025.11.033_bib125","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40262-021-01079-x","article-title":"Real-life population pharmacokinetics of recombinant factor XIII and dosing considerations for preventing the risk of bleeding in patients with FXIII congenital deficiency","volume":"61","author":"Cojutti","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2025.11.033_bib126","doi-asserted-by":"crossref","first-page":"10164","DOI":"10.1021\/bi00106a013","article-title":"Inhibition of factor XIII activation by an anti-peptide monoclonal antibody","volume":"30","author":"Lukacova","year":"1991","journal-title":"Biochemistry"},{"key":"10.1016\/j.jtha.2025.11.033_bib127","doi-asserted-by":"crossref","first-page":"10109","DOI":"10.1021\/bi00199a039","article-title":"Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation","volume":"33","author":"Freund","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.jtha.2025.11.033_bib128","doi-asserted-by":"crossref","first-page":"204","DOI":"10.7164\/antibiotics.46.204","article-title":"A simple and rapid screen for inhibitors of factor XIIIa","volume":"46","author":"Tymiak","year":"1993","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.jtha.2025.11.033_bib129","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejmech.2015.05.019","article-title":"(\u00b1) cis-bisamido epoxides: a novel series of potent FXIII-A inhibitors","volume":"98","author":"Avery","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jtha.2025.11.033_bib130","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1749-6632.1981.tb29789.x","article-title":"alpha-Halogenmethyl carbonyl compounds as very potent inhibitors of factor XIIIa in vitro","volume":"370","author":"Reinhardt","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jtha.2025.11.033_bib131","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1021\/ja992355s","article-title":"Alutacenoic acids A and B, rare naturally occurring cyclopropenone derivatives isolated from fungi: potent non-peptide factor XIIIa inhibitors","volume":"122","author":"Kogen","year":"2000","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.jtha.2025.11.033_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2020.113708","article-title":"Inhibitors of blood coagulation factor XIII","volume":"605","author":"Schmitz","year":"2020","journal-title":"Anal Biochem"},{"key":"10.1016\/j.jtha.2025.11.033_bib133","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1042\/bj3240797","article-title":"Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood-sucking leech Haementeria ghilianii","volume":"324","author":"Finney","year":"1997","journal-title":"Biochem J"},{"key":"10.1016\/j.jtha.2025.11.033_bib134","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cmdc.201100405","article-title":"Synthesis and functional characterization of tridegin and its analogues: inhibitors and substrates of factor XIIIa","volume":"7","author":"B\u00f6hm","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jtha.2025.11.033_bib135","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/jth.14646","article-title":"Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a)","volume":"18","author":"Pasternack","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib136","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood.V79.9.2340.2340","article-title":"Direct detection of activated protein C in blood from human subjects","volume":"79","author":"Gruber","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib137","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1172\/JCI110385","article-title":"Deficiency of protein C in congenital thrombotic disease","volume":"68","author":"Griffin","year":"1981","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtha.2025.11.033_bib138","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Efficacy and safety of recombinant human activated protein C for severe sepsis","volume":"344","author":"Bernard","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib139","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","article-title":"Drotrecogin alfa (activated) in adults with septic shock","volume":"366","author":"Ranieri","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib140","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1111\/jth.15025","article-title":"Anticoagulant protein S\u2014new insights on interactions and functions","volume":"18","author":"Gierula","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib141","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.290.2.238","article-title":"Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial","volume":"290","author":"Abraham","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.11.033_bib142","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1164\/rccm.201007-1167OC","article-title":"Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial","volume":"183","author":"Wunderink","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib143","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0009-3084(94)90157-0","article-title":"Overview on fibrinolysis: plasminogen activation pathways on fibrin and cell surfaces","volume":"67\u201368","author":"Angl\u00e9s-Cano","year":"1994","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.jtha.2025.11.033_bib144","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0741-5214(94)70105-9","article-title":"Plasminogen acceleration of urokinase thrombolysis","volume":"19","author":"Stoughton","year":"1994","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jtha.2025.11.033_bib145","doi-asserted-by":"crossref","first-page":"26150","DOI":"10.1016\/S0021-9258(18)35729-6","article-title":"Lys-plasminogen is a significant intermediate in the activation of glu-plasminogen during fibrinolysis in vitro","volume":"267","author":"Fredenburgh","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2025.11.033_bib146","doi-asserted-by":"crossref","first-page":"27176","DOI":"10.1074\/jbc.273.42.27176","article-title":"A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor","volume":"273","author":"Wang","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2025.11.033_bib147","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2141.2005.05444.x","article-title":"Molecular mechanisms of fibrinolysis","volume":"129","author":"Cesarman-Maus","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.11.033_bib148","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0140-6736(99)07403-6","article-title":"Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial","volume":"354","author":"Van de Werf","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.11.033_bib149","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1073\/pnas.91.9.3670","article-title":"A faster-acting and more potent form of tissue plasminogen activator","volume":"91","author":"Keyt","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2025.11.033_bib150","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(22)02600-9","article-title":"Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial","volume":"401","author":"Wang","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.11.033_bib151","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1056\/NEJMoa2400314","article-title":"Reteplase versus alteplase for acute ischemic stroke","volume":"390","author":"Li","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib152","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa2402980","article-title":"Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy","volume":"391","author":"Xiong","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib153","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2014.5990","article-title":"Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis","volume":"311","author":"Chatterjee","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.11.033_bib154","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ahj.2023.09.002","article-title":"Randomized controlled trial of mechanical thrombectomy vs catheter-directed thrombolysis for acute hemodynamically stable pulmonary embolism: rationale and design of the PEERLESS study","volume":"266","author":"Gonsalves","year":"2023","journal-title":"Am Heart J"},{"key":"10.1016\/j.jtha.2025.11.033_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2025.109420","article-title":"Thrombectomy in high-risk pulmonary embolism\u2014device versus thrombolysis: rationale and design of the TORPEDO-NL investigator-initiated, academically-sponsored, multicenter, open-label randomized controlled trial","volume":"255","author":"Stenger","year":"2025","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.11.033_bib156","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.jcin.2015.04.020","article-title":"A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: the SEATTLE II study","volume":"8","author":"Piazza","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jtha.2025.11.033_bib157","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa1615066","article-title":"Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis","volume":"377","author":"Vedantham","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib158","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018973","article-title":"CAVA (ultrasound-accelerated catheter-directed thrombolysis on preventing post-thrombotic syndrome) trial: long-term follow-up results","volume":"10","author":"Notten","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2025.11.033_bib159","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1182\/blood-2010-08-303677","article-title":"Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model","volume":"117","author":"Vercauteren","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib160","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.thromres.2018.06.010","article-title":"Fibrinolytic potential of DS-1040, a novel orally available inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)","volume":"168","author":"Noguchi","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.11.033_bib161","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/jth.13658","article-title":"A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects","volume":"15","author":"Zhou","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib162","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.thromres.2021.06.007","article-title":"S62798, a potent TAFIa inhibitor, accelerates endogenous fibrinolysis in a murine model of pulmonary thromboembolism","volume":"204","author":"Sansilvestri-Morel","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.11.033_bib163","series-title":"GeneReviews","article-title":"Complete plasminogen activator inhibitor 1 deficiency","author":"Heiman","year":"1993"},{"key":"10.1016\/j.jtha.2025.11.033_bib164","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1111\/jcmm.12875","article-title":"A specific plasminogen activator inhibitor-1 antagonist derived from inactivated urokinase","volume":"20","author":"Gong","year":"2016","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jtha.2025.11.033_bib165","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1111\/j.1538-7836.2008.03137.x","article-title":"Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody","volume":"6","author":"Develter","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.033_bib166","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2014-07-588319","article-title":"Innovative thrombolytic strategy using a heterodimer diabody against TAFI and PAI-1 in mouse models of thrombosis and stroke","volume":"125","author":"Wyseure","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.033_bib167","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/j.1365-2516.2008.01766.x","article-title":"Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance","volume":"14","author":"Carpenter","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.11.033_bib168","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.expneurol.2014.02.009","article-title":"Reversing the deleterious effects of \u03b12-antiplasmin on tissue plasminogen activator therapy improves outcomes in experimental ischemic stroke","volume":"255","author":"Houng","year":"2014","journal-title":"Exp Neurol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625009195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625009195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:18:51Z","timestamp":1781939931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625009195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":169,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1538783625009195"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.11.033","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel and experimental anticoagulant strategies beyond current direct oral anticoagulants","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.11.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}